Inhibition of receptor activator of NF-κB ligand by denosumab attenuates vascular calcium deposition in mice

American Journal of Pathology

Volumn 175, Issue 2, 2009, Pages 473-478

  Helas, Susann ^a   Goettsch, Claudia ^a   Schoppet, Michael ^c   Zeitz, Ute ^d   Hempel, Ute ^b   Morawietz, Henning ^a   Kostenuik, Paul J ^e   Erben, Reinhold G ^d   Hofbauer, Lorenz C ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^e AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; DENOSUMAB; DEOXYPYRIDINOLINE; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO; PREDNISOLONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD VESSEL CALCIFICATION; BONE DENSITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; HEART PROTECTION; IMPLANTATION; LUMBAR SPINE; MORPHOLOGY; MOUSE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; URINARY EXCRETION; WILD TYPE;

EID: 68449102008     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.080957     Document Type: Article

References (24)

1. Naves M, Rodriguez-Garcia M, Diaz-Lopez JB, Gomez-Alonso C, Cannata-Andia JB: Progression of vascular calcifications is associated with greater bone loss and increased bone fractures. Osteoporos Int 2008, 19:1161-1166
2. Doherty TM, Fitzpatrick LA, Inoue D, Qiao JH, Fishbein MC, Detrano RC, Shah PK, Rajavashisth TB: Molecular, endocrine, and genetic mechanisms of arterial calcification. Endocr Rev 2004, 25:629-672
3. Kaden JJ, Bickelhaupt S, Grobholz R, Haase KK, Sarikoc A, Kilic R, Brueckmann M, Lang S, Zahn I, Vahl C, Hagl S, Dempfle CE, Borggrefe M: Receptor activator of nuclear factor κB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol 2004, 36:57-66
4. Hofbauer LC, Brueck CC, Shanahan CM, Schoppet M, Dobnig H: Vascular calcification and osteoporosis-from clinical observation towards molecular understanding. Osteoporos Int 2007, 18:251-259
5. Hofbauer LC, Schoppet M: Clinical implications of the osteoprotegerin/ RANKL/RANK system for bone and vascular diseases. JAMA 2004, 292:490-495
6. Canalis E, Mazziotti G, Giustina A, Bilezikian JP: Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007, 18:1319-1328
7. Kirton JP, Wilkinson FL, Canfield AE, Alexander MY: Dexamethasone downregulates calcification-inhibitor molecules and accelerates osteogenic differentiation of vascular pericytes: implications for vascular calcification. Circ Res 2006, 98:1264-1272
8. Mori K, Shioi A, Jono S, Nishizawa Y, Morii H: Dexamethasone enhances in vitro vascular calcification by promoting osteoblastic differentiation of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999, 19:2112-2118
9. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ: Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006, 354:821-831
10. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM: A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004, 19:1059-1066
11. Kostenuik PJ, Nguyen HQ, McCabe J, Warimgton K, Kurahara C, Sun N, Chen C, Li L, Cattley RC, Van G, Scully S, Elliott R, Grisanti M, Morony S, Tan HL, Asuncion F, Li X, Ominsky MS, Stolina M, Dwyer D, Dougall WC, Hawkins N, Boyle WJ, Simonet WS, Sullivan JK: Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases bone density in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 2008, 24:153-161
12. Schoppet M, Shroff RC, Hofbauer LC, Shanahan CM: Exploring the biology of vascular calcification in chronic kidney disease: what's circulating? Kidney Int 2008, 73:384-390
13. Hofbauer LC, Zeitz U, Schoppet M, Skalicky M, Schueler C, Stolina M, Kostenuik PJ, Erben RG: Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL. Arthritis Rheum 2009, 60:1427-1437
14. Hofbauer LC, Schrader J, Niebergall U, Viereck V, Burchert A, Horsch D, Preissner KT, Schoppet M: Interleukin-4 differentially regulates osteoprotegerin expression and induces calcification in vascular smooth muscle cells. Thromb Haemost 2006, 95:708-714
15. Price PA, June HH, Buckley JR, Williamson MK: Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 2001, 21:1610-1616
16. Shroff RC, McNair R, Figg N, Skepper JN, Schurgers L, Gupta A, Hiorns M, Donald AE, Deanfield J, Rees L, Shanahan CM: Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 2008, 118:1748-1757
17. Price PA, Faus SA, Williamson MK: Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 2001, 21:817-824
18. Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, Jahnen-Dechent W: The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003, 112:357-366
19. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997, 390:45-51
20. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS: Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000, 192:463-474
21. Morony S, Tintut Y, Zhang Z, Cattley RC, Van G, Dwyer D, Stolina M, Kostenuik PJ, Demer LL: Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation 2008, 117:411-420
22. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR: Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998, 273:14363-14367
23. Nybo M, Rasmussen L: The capability of plasma Osteoprotegerin as a predictor of cardiovascular disease: A systematic literature review. Eur J Endocrinol 2008, 159:603-608
24. -/ - mice. Arterioscler Thromb Vasc Biol 2006, 26:2117-2124